Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

MorphoSys : Announces Approvals for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Brazil and Australia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/05/2018 | 10:15am EDT

DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval
MorphoSys Announces Approvals for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Brazil and Australia (news with additional features)

05.04.2018 / 16:07
The issuer is solely responsible for the content of this announcement.


Planegg/Munich, Germany, April 5, 2018

MorphoSys Announces Approvals for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Brazil and Australia

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that country subsidiaries of its licensee Janssen reported that Tremfya(R) (guselkumab) has been approved for the treatment of adults living with moderate to severe plaque psoriasis in Brazil and Australia.

As reported by Janssen-Cilag Farmacêutica Ltda. (Janssen), the Brazilian National Health Surveillance Agency ("ANVISA") has approved Tremfya(R) for the treatment of adults living with moderate to severe plaque psoriasis. Janssen-Cilag Pty Limited (Janssen) announced that Tremfya(R) has been approved by the Therapeutic Goods Administration (TGA) and registered on the Australian Register of Therapeutic Goods (ARTG) for the treatment of adults living with moderate to severe plaque psoriasis in Australia.

Tremfya(R) is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology.

MorphoSys is eligible to receive royalties on net sales of Tremfya(R).

Dr. Markus Enzelberger, Chief Scientifc Officer of MorphoSys AG, said: "We are very pleased about the Tremfya(R) approvals in Brazil and Australia. Thus Tremfya(R) has now been approved in a number of territories worldwide, including the U.S., Canada, the European Union, Brazil, and Australia. We expect Tremfya(R) will continue to provide an important treatment option for patients living with moderate-to-severe plaque psoriasis."

In addition to psoriasis, Tremfya(R) is in Phase 3 development in psoriatic arthritis. Janssen has announced plans to investigate guselkumab in Crohn's disease.

Further information about the approvals of Tremfya(R) in Brazil and Australia can be found in press releases issued by Janssen.

About Psoriasis
Psoriasis is a chronic, autoimmune inflammatory disorder that results in the overproduction of skin cells, characterised by raised, inflamed, scaly, red lesions, or plaques, which can cause itching and physical pain. It is estimated that as many as 125 million people worldwide have psoriasis, and approximately 20% of people affected have cases that are considered moderate to severe. According to Janssen about five million people in Brazil are expected to be impacted by psoriasis.

About MorphoSys
MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on its technological leadership in generating antibodies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. This broad pipeline spans MorphoSys's two business segments: Proprietary Development, in which the Company invests in product candidates for its own account, and Partnered Discovery, in which product candidates are developed exclusively for our a variety of Pharma and Biotech partners. In 2017, Tremfya(R) (guselkumab), marketed by Janssen, became the first therapeutic antibody based on MorphoSys's proprietary technology to receive marketing approval for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union and Canada. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.
Tremfya(R) is a trademark of Janssen Biotech, Inc.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Jochen Orlowski
Associate Director Corporate Communications & IR

Alexandra Goller
Associate Director Corporate Communications & IR

Dr. Claudia Gutjahr-Loeser
Investor Relations Officer

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=SEXFEPAMGA
Document title: Media Release


05.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

671663  05.04.2018 

fncls.ssp?fn=show_t_gif&application_id=671663&application_name=news&site_id=zonebourse

© EQS 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
05/24MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/24MORPHOSYS : to Present at Upcoming Investor Conferences
AQ
05/23MORPHOSYS : to Present at Upcoming Investor Conferences
EQ
05/23MORPHOSYS AG : Reports Outcome of Annual General Meeting 2019
AQ
05/22MORPHOSYS : Reports Outcome of Annual General Meeting 2019
EQ
05/16MORPHOSYS AG : Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasi..
EQ
05/16MORPHOSYS AG : Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (M..
EQ
05/14MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/09MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/08MORPHOSYS AG : Reports First Quarter 2019 Results
AQ
More news
Financials (€)
Sales 2019 71,9 M
EBIT 2019 -96,6 M
Net income 2019 -91,7 M
Finance 2019 381 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 36,2x
EV / Sales 2020 24,2x
Capitalization 2 983 M
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 95,4 €
Spread / Average Target 1,8%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG5.34%3 342
IQVIA HOLDINGS INC17.40%26 900
LONZA GROUP24.03%23 473
CELLTRION, INC.--.--%19 604
INCYTE CORPORATION28.56%17 530
EXACT SCIENCES CORPORATION48.97%12 511